Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma

Ubiquitin-activating enzyme inhibition induces an unfolded protein response and overcomes drug resistance in myeloma

(2019) Junling Zhuang et al.   BLOOD

New Drugs in Multiple Myeloma

(2019) Chutima Kunacheewa et al.   Annual Review of Medicine

Reactive Oxygen Species and Oncoprotein Signaling-A Dangerous Liaison

(2018) Stephen Jun Fei Chong et al.   ANTIOXIDANTS & REDOX SIGNALING

The unfolded protein response as a target for anticancer therapeutics

(2018) Mengxiong Wang et al.   CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY

Trametinib inhibits RAS -mutant MLL -rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo

(2018) Mark Kerstjens et al.   HAEMATOLOGICA

The Unfolded Protein Response and Cell Fate Control

(2018) Claudio Hetz et al.   MOLECULAR CELL

Trametinib inhibits RAS -mutant MLL -rearranged acute lymphoblastic leukemia at specific niche sites and reduces ERK phosphorylation in vivo

(2018) Mark Kerstjens et al.   HAEMATOLOGICA

Proteasome inhibitors in cancer therapy

(2017) Elisabet E. Manasanch et al.   Nature Reviews Clinical Oncology

The varied distribution and impact of RAS codon and other key DNA alterations across the translocation cyclin D subgroups in multiple myeloma

(2017) Caleb K. Stein et al.   Oncotarget

Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes

(2016) K. M. Kortum et al.   BLOOD

Tight Junction Protein 1 Modulates Proteasome Capacity and Proteasome Inhibitor Sensitivity in Multiple Myeloma via EGFR/JAK1/STAT3 Signaling

(2016) Xing-Ding Zhang et al.   CANCER CELL

Integration of Novel Agents into the Care of Patients with Multiple Myeloma

(2016) Robert Z. Orlowski et al.   CLINICAL CANCER RESEARCH

The Transcription Factor ATF5 Mediates a Mammalian Mitochondrial UPR

(2016) Christopher J. Fiorese et al.   CURRENT BIOLOGY

Vemurafenib in combination with cobimetinib in relapsed and refractory extramedullary multiple myeloma harboring the BRAF V600E mutation

(2016) Ulrich J.M. Mey et al.   HEMATOLOGICAL ONCOLOGY

Circulating tumour DNA analysis demonstrates spatial mutational heterogeneity that coincides with disease relapse in myeloma

(2016) S Mithraprabhu et al.   LEUKEMIA

The complexities and versatility of the RAS-to-ERK signalling system in normal and cancer cells

(2016) Dirk Fey et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Ras signaling through RASSF proteins

(2016) Howard Donninger et al.   SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY

Frontline therapy of multiple myeloma

(2015) P. Moreau et al.   BLOOD

Cancer statistics, 2015

(2015) Rebecca L. Siegel et al.   CA-A CANCER JOURNAL FOR CLINICIANS

A Phase II Trial of AZD6244 (Selumetinib, ARRY-142886), an Oral MEK1/2 Inhibitor, in Relapsed/Refractory Multiple Myeloma

(2015) B. Holkova et al.   CLINICAL CANCER RESEARCH

The Nuclear Factor (Erythroid-derived 2)-like 2 and Proteasome Maturation Protein Axis Mediate Bortezomib Resistance in Multiple Myeloma

(2015) Bingzong Li et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma

(2015) Brian A. Walker et al.   JOURNAL OF CLINICAL ONCOLOGY

Inhibiting MEK in MAPK pathway-activated myeloma

(2015) C J Heuck et al.   LEUKEMIA

Understanding biology to tackle the disease: Multiple myeloma from bench to bedside, and back

(2014) Giada Bianchi et al.   CA-A CANCER JOURNAL FOR CLINICIANS

Phase I study of the MEK inhibitor trametinib in combination with the AKT inhibitor afuresertib in patients with solid tumors and multiple myeloma

(2014) Anthony W. Tolcher et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Vemurafenib Response in 2 Patients With Posttransplant Refractory BRAF V600E–Mutated Multiple Myeloma

(2014) J.P. Sharman et al.   Clinical Lymphoma Myeloma & Leukemia

Heterogeneity of genomic evolution and mutational profiles in multiple myeloma

(2014) Niccolo Bolli et al.   Nature Communications

Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy

(2013) G. Mulligan et al.   BLOOD

Xbp1s-Negative Tumor B Cells and Pre-Plasmablasts Mediate Therapeutic Proteasome Inhibitor Resistance in Multiple Myeloma

(2013) Chungyee Leung-Hagesteijn et al.   CANCER CELL

Discovery of a Selective Kinase Inhibitor (TAK-632) Targeting Pan-RAF Inhibition: Design, Synthesis, and Biological Evaluation of C-7-Substituted 1,3-Benzothiazole Derivatives

(2013) Masanori Okaniwa et al.   JOURNAL OF MEDICINAL CHEMISTRY

Targeting the BRAF V600E Mutation in Multiple Myeloma

(2013) M. Andrulis et al.   Cancer Discovery

Nrf2-dependent Induction of Proteasome and Pa28αβ Regulator Are Required for Adaptation to Oxidative Stress

(2012) Andrew M. Pickering et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

HDM-2 inhibition suppresses expression of ribonucleotide reductase subunit M2, and synergistically enhances gemcitabine-induced cytotoxicity in mantle cell lymphoma

(2011) R. J. Jones et al.   BLOOD

Initial genome sequencing and analysis of multiple myeloma

(2011) Michael A. Chapman et al.   NATURE

The immunoproteasome, the 20S proteasome and the PA28αβ proteasome regulator are oxidative-stress-adaptive proteolytic complexes

(2010) Andrew M. Pickering et al.   BIOCHEMICAL JOURNAL

Mutated RAS and constitutively activated Akt delineate distinct oncogenic pathways, which independently contribute to multiple myeloma cell survival

(2010) T. Steinbrunn et al.   BLOOD

PR-924, a selective inhibitor of the immunoproteasome subunit LMP-7, blocks multiple myeloma cell growth both in vitro and in vivo

(2010) Ajita V. Singh et al.   BRITISH JOURNAL OF HAEMATOLOGY

Evidence of a Role for Activation of Wnt/β-Catenin Signaling in the Resistance of Plasma Cells to Lenalidomide

(2010) Chad C. Bjorklund et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

The proteasome load versus capacity balance determines apoptotic sensitivity of multiple myeloma cells to proteasome inhibition

(2009) G. Bianchi et al.   BLOOD

Future of Cancer Incidence in the United States: Burdens Upon an Aging, Changing Nation

(2009) Benjamin D. Smith et al.   JOURNAL OF CLINICAL ONCOLOGY

Overlapping promoter targeting by Elk-1 and other divergent ETS-domain transcription factor family members

(2009) Joanna Boros et al.   NUCLEIC ACIDS RESEARCH

Targeted inhibition of the immunoproteasome is a potent strategy against models of multiple myeloma that overcomes resistance to conventional drugs and nonspecific proteasome inhibitors

(2008) Deborah J. Kuhn et al.   BLOOD